BRPI0922708A2 - peptídeos mini-hepcidina e métodos de uso do mesmo - Google Patents

peptídeos mini-hepcidina e métodos de uso do mesmo

Info

Publication number
BRPI0922708A2
BRPI0922708A2 BRPI0922708A BRPI0922708A BRPI0922708A2 BR PI0922708 A2 BRPI0922708 A2 BR PI0922708A2 BR PI0922708 A BRPI0922708 A BR PI0922708A BR PI0922708 A BRPI0922708 A BR PI0922708A BR PI0922708 A2 BRPI0922708 A2 BR PI0922708A2
Authority
BR
Brazil
Prior art keywords
minihepidine
peptides
methods
minihepidine peptides
Prior art date
Application number
BRPI0922708A
Other languages
English (en)
Inventor
Nemeth Elizabeta
Preza Gloria
Ruchala Piotr
Ganz Tomas
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BRPI0922708A2 publication Critical patent/BRPI0922708A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0922708A 2008-12-05 2009-12-04 peptídeos mini-hepcidina e métodos de uso do mesmo BRPI0922708A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12027708P 2008-12-05 2008-12-05
PCT/US2009/066711 WO2010065815A2 (en) 2008-12-05 2009-12-04 Mini-hepcidin peptides and methods of using thereof

Publications (1)

Publication Number Publication Date
BRPI0922708A2 true BRPI0922708A2 (pt) 2018-11-06

Family

ID=42233878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922708A BRPI0922708A2 (pt) 2008-12-05 2009-12-04 peptídeos mini-hepcidina e métodos de uso do mesmo

Country Status (6)

Country Link
US (2) US8435941B2 (pt)
EP (2) EP2373679B1 (pt)
CN (1) CN102245626A (pt)
AU (1) AU2009322260B2 (pt)
BR (1) BRPI0922708A2 (pt)
WO (1) WO2010065815A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002321105A1 (en) 2001-05-25 2002-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
CN102245626A (zh) * 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
CN101955525B (zh) * 2010-07-13 2012-11-07 中国农业科学院兰州畜牧与兽药研究所 一种人工抗菌肽及其基因与制备方法
US9551720B2 (en) * 2011-01-26 2017-01-24 University of Pittsburgh—Of the Commonwaelth System of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
HK1199892A1 (en) * 2011-12-09 2015-07-24 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
ES2731609T3 (es) * 2012-11-01 2019-11-18 Univ California Polipéptidos ERFE y eritroferrona y métodos de regulación del metabolismo del hierro
GB201302837D0 (en) * 2013-02-19 2013-04-03 Univ Singapore Therapeutic Agents
RS62633B1 (sr) 2013-03-15 2021-12-31 Protagonist Therapeutics Inc Analozi hepcidina i njihove primene
KR102218494B1 (ko) * 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
JP2017519810A (ja) * 2014-04-07 2017-07-20 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ ヘプシジン模倣ペプチドおよびその使用
SI3143037T1 (sl) 2014-05-16 2021-11-30 Protagonist Therapeutics, Inc. Antagonisti integrin alpha4beta7 tioeterskih peptidov
AU2015279571A1 (en) * 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
EP3240799B1 (en) * 2014-12-29 2021-03-31 The Regents of the University of California S-alkylated hepcidin peptides and methods of making and using thereof
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
KR20180109917A (ko) * 2016-01-08 2018-10-08 라 졸라 파마슈티칼 컴파니 헵시딘의 투여 방법
WO2017165676A1 (en) 2016-03-23 2017-09-28 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS
US20190284274A1 (en) * 2016-08-05 2019-09-19 Silarus Therapeutics, Inc. Erfe specific antibodies compositions and methods of use
US20180099023A1 (en) * 2016-09-06 2018-04-12 La Jolla Pharmaceutical Company Methods of treating iron overload
WO2018107241A1 (en) * 2016-12-16 2018-06-21 The University Of Sydney Treatment of iron disorders
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
WO2018175633A1 (en) * 2017-03-22 2018-09-27 La Jolla Pharmaceutical Company Methods of inducing anti-malarial immune responses and compositions related thereto
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
EP3820883A4 (en) 2018-07-12 2022-04-20 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso
CN116082455A (zh) 2019-07-10 2023-05-09 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
EP4090669A4 (en) 2020-01-15 2024-11-20 Janssen Biotech, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES
SI4090670T1 (sl) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni
WO2021222363A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
CA3181583A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
US12559502B2 (en) 2020-04-28 2026-02-24 Global Blood Therapeutics, Inc Thieno pyrimidines as ferroportin inhibitors
WO2022003238A1 (en) * 2020-07-02 2022-01-06 Tampere University Foundation Sr Renin-based analysis of hepcidin
IL316550A (en) 2020-11-20 2024-12-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
WO2022154121A1 (ja) * 2021-01-18 2022-07-21 富士フイルム和光純薬株式会社 ヘプシジンの吸着抑制剤、吸着抑制方法、標準品、試薬、キットおよび測定方法
EP4314014A4 (en) * 2021-04-01 2025-03-05 Protagonist Therapeutics, Inc. HEPCIDIN MIMETICS CONJUGATES
IL310061A (en) 2021-07-14 2024-03-01 Janssen Biotech Inc Peptide inhibitors linked to fatty residues of the interleukin-23 receptor
CN115703826B (zh) * 2021-08-03 2025-05-06 浙江大学 铁调素改造体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739274A (en) * 1992-06-12 1998-04-14 Cv Technologies, Inc. Active component of parathyroid hypertensive factor
JP2891023B2 (ja) * 1993-03-09 1999-05-17 味の素株式会社 ランチオニン含有物の製造方法
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
RU2359268C2 (ru) 2002-11-19 2009-06-20 ДиАрДжи ИНТЕРНЭШНЛ, ИНК. Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение
CA2522680A1 (en) 2003-04-15 2004-10-28 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
US7534764B2 (en) 2005-06-29 2009-05-19 The Regents Of The University Of California Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
MX2009008104A (es) 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
CN102245626A (zh) * 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
HK1199892A1 (en) * 2011-12-09 2015-07-24 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof

Also Published As

Publication number Publication date
EP2373679A2 (en) 2011-10-12
AU2009322260B2 (en) 2013-09-12
WO2010065815A3 (en) 2010-10-21
WO2010065815A2 (en) 2010-06-10
EP3208279B1 (en) 2021-04-21
US20130203662A1 (en) 2013-08-08
US20120040894A1 (en) 2012-02-16
CN102245626A (zh) 2011-11-16
EP3208279A1 (en) 2017-08-23
EP2373679B1 (en) 2017-03-08
US8435941B2 (en) 2013-05-07
AU2009322260A1 (en) 2011-07-07
EP2373679A4 (en) 2012-05-30

Similar Documents

Publication Publication Date Title
BRPI0922708A2 (pt) peptídeos mini-hepcidina e métodos de uso do mesmo
BRPI1007175A2 (pt) Polipeptídeos hidroxifenilpriruvato dioxigenase mutantes e métodos de uso
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
DOP2010000260A (es) Derivado heterociclico fusionado y su uso
PT2424896E (pt) Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
BRPI0915717A2 (pt) ferramenta de avaliação de cascalho e métodos de uso
BR112013014321A2 (pt) moduladores inovadores e métodos de uso
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI1011384A2 (pt) pro-proteinas e seus metodos de uso
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0916735A2 (pt) moduladores de tgr5 e métodos de uso do mesmo
BRPI1012676A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI1012560A2 (pt) anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
BRPI0921992A2 (pt) moduladores tgr5 e métodos de uso destes
BRPI1007494A2 (pt) composto e uso do mesmo
PT2247620T (pt) Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
BRPI0816835A2 (pt) dispositivo de pulverização e método de uso do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.